533 related articles for article (PubMed ID: 27958595)
21. Schwannomatosis: a genetic and epidemiological study.
Evans DG; Bowers NL; Tobi S; Hartley C; Wallace AJ; King AT; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Freeman SR; Ealing J; Kellett M; Laitt R; Thomas O; Halliday D; Ferner R; Taylor A; Duff C; Harkness EF; Smith MJ
J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1215-1219. PubMed ID: 29909380
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis type 2.
Evans GR; Lloyd SKW; Ramsden RT
Adv Otorhinolaryngol; 2011; 70():91-98. PubMed ID: 21358190
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2.
Walter J; Kuhn SA; Brodhun M; Reichart R; Kalff R
Clin Neurol Neurosurg; 2009 Jun; 111(5):454-9. PubMed ID: 19249154
[TBL] [Abstract][Full Text] [Related]
24. [Neurofibromatosis type 2].
Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
[TBL] [Abstract][Full Text] [Related]
25. Astrocytic hamartoma of the optic disc and multiple café-au-lait macules in a child with neurofibromatosis type 2.
Sachdeva R; Rothner DA; Traboulsi EI; Hayden BC; Rychwalski PJ
Ophthalmic Genet; 2010 Dec; 31(4):209-14. PubMed ID: 21067482
[TBL] [Abstract][Full Text] [Related]
26. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.
Kehrer-Sawatzki H; Farschtschi S; Mautner VF; Cooper DN
Hum Genet; 2017 Feb; 136(2):129-148. PubMed ID: 27921248
[TBL] [Abstract][Full Text] [Related]
27. [Neurofibromatosis].
Wolkenstein P; Decq P
Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
[TBL] [Abstract][Full Text] [Related]
28. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
29. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
30. [Neurofibromatosis type 2 in the otorhinolaryngological practice].
Subbotina MV; Berseneva AV
Vestn Otorinolaringol; 2024; 89(1):37-41. PubMed ID: 38506024
[TBL] [Abstract][Full Text] [Related]
31. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2.
Sperfeld AD; Hein C; Schröder JM; Ludolph AC; Hanemann CO
Brain; 2002 May; 125(Pt 5):996-1004. PubMed ID: 11960890
[TBL] [Abstract][Full Text] [Related]
32. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
[TBL] [Abstract][Full Text] [Related]
33. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
Castellanos E; Bielsa I; Carrato C; Rosas I; Solanes A; Hostalot C; Amilibia E; Prades J; Roca-Ribas F; Lázaro C; Blanco I; Serra E;
BMC Med Genomics; 2015 Jan; 8():2. PubMed ID: 25739810
[TBL] [Abstract][Full Text] [Related]
34. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
35. [Pathogenesis and molecular pathology of vestibular schwannoma].
Brodhun M; Stahn V; Harder A
HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
[TBL] [Abstract][Full Text] [Related]
36. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
37. Paediatric presentation of type 2 neurofibromatosis.
Evans DG; Birch JM; Ramsden RT
Arch Dis Child; 1999 Dec; 81(6):496-9. PubMed ID: 10569966
[TBL] [Abstract][Full Text] [Related]
38. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.
Louis DN; Ramesh V; Gusella JF
Brain Pathol; 1995 Apr; 5(2):163-72. PubMed ID: 7670657
[TBL] [Abstract][Full Text] [Related]
39. Advances in the treatment of neurofibromatosis-associated tumours.
Lin AL; Gutmann DH
Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
[TBL] [Abstract][Full Text] [Related]
40. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
